D. Wunderlich

2.2k total citations
39 papers, 1.7k citations indexed

About

D. Wunderlich is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, D. Wunderlich has authored 39 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Radiology, Nuclear Medicine and Imaging, 16 papers in Immunology and 13 papers in Molecular Biology. Recurrent topics in D. Wunderlich's work include Monoclonal and Polyclonal Antibodies Research (17 papers), Glycosylation and Glycoproteins Research (6 papers) and Immunotherapy and Immune Responses (6 papers). D. Wunderlich is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (17 papers), Glycosylation and Glycoproteins Research (6 papers) and Immunotherapy and Immune Responses (6 papers). D. Wunderlich collaborates with scholars based in United States, Germany and Switzerland. D. Wunderlich's co-authors include Jeffrey Schlom, Raffaella Muraro, Ann D. Thor, Y A Teramoto, Patricia Horan Hand, Arnaldo Caruso, P. Noguchi, David Colcher, James R. Bloedel and Jean F. Simpson and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The EMBO Journal.

In The Last Decade

D. Wunderlich

39 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Wunderlich United States 21 663 629 456 454 165 39 1.7k
S M Hsu United States 17 655 1.0× 326 0.5× 744 1.6× 357 0.8× 519 3.1× 22 2.2k
John R. Adair United Kingdom 16 628 0.9× 733 1.2× 266 0.6× 262 0.6× 75 0.5× 32 1.4k
Sylvia Hu United States 19 2.0k 3.0× 505 0.8× 357 0.8× 1.1k 2.5× 101 0.6× 32 3.4k
Hajime Inomata Japan 28 866 1.3× 826 1.3× 141 0.3× 84 0.2× 116 0.7× 84 2.9k
Susan F. Radka United States 19 1.2k 1.7× 204 0.3× 837 1.8× 375 0.8× 116 0.7× 38 2.5k
Nathalie Renard France 20 552 0.8× 116 0.2× 536 1.2× 570 1.3× 109 0.7× 45 1.7k
Elaine M. Elder United States 24 1.0k 1.5× 133 0.2× 794 1.7× 611 1.3× 54 0.3× 41 2.5k
Gemma M. Dingjan Netherlands 26 716 1.1× 146 0.2× 1.0k 2.3× 286 0.6× 228 1.4× 37 2.1k
Bruce R. Ksander United States 39 1.5k 2.3× 944 1.5× 1.5k 3.2× 629 1.4× 55 0.3× 121 4.3k
Dimitrios Arvanitis Greece 21 430 0.6× 171 0.3× 122 0.3× 245 0.5× 138 0.8× 77 1.6k

Countries citing papers authored by D. Wunderlich

Since Specialization
Citations

This map shows the geographic impact of D. Wunderlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Wunderlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Wunderlich more than expected).

Fields of papers citing papers by D. Wunderlich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Wunderlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Wunderlich. The network helps show where D. Wunderlich may publish in the future.

Co-authorship network of co-authors of D. Wunderlich

This figure shows the co-authorship network connecting the top 25 collaborators of D. Wunderlich. A scholar is included among the top collaborators of D. Wunderlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Wunderlich. D. Wunderlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noel, Marcus Smith, Maeve A. Lowery, David P. Ryan, et al.. (2017). Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma. Annals of Oncology. 28. v257–v257. 8 indexed citations
2.
Zhu, Ming, Susan Pleasic‐Williams, Tsung H. Lin, et al.. (2013). pSTAT3: a target biomarker to study the pharmacology of the anti-IL-21R antibody ATR-107 in human whole blood. Journal of Translational Medicine. 11(1). 65–65. 11 indexed citations
3.
Michel, J. F., et al.. (2001). Interleukin‐4 polymorphisms in early onset periodontitis. Journal Of Clinical Periodontology. 28(5). 483–488. 66 indexed citations
4.
5.
Bracha, Vlastislav, Kristina B. Irwin, Michelle Webster, et al.. (1998). Microinjections of anisomycin into the intermediate cerebellum during learning affect the acquisition of classically conditioned responses in the rabbit. Brain Research. 788(1-2). 169–178. 48 indexed citations
6.
Kagerer, Florian A., Vlastislav Bracha, D. Wunderlich, George E. Stelmach, & James R. Bloedel. (1998). Ataxia reflected in the simulated movements of patients with cerebellar lesions. Experimental Brain Research. 121(2). 125–134. 32 indexed citations
7.
Rand, Miya K., D. Wunderlich, Philip E. Martin, George E. Stelmach, & James R. Bloedel. (1998). Adaptive changes in responses to repeated locomotor perturbations in cerebellar patients. Experimental Brain Research. 122(1). 31–43. 33 indexed citations
8.
Wunderlich, D.. (1997). Argument extension by lexical adjunction. Journal of Semantics. 14(2). 95–142. 48 indexed citations
9.
Buggy, Joseph J., et al.. (1996). Human Glucagon Receptor Monoclonal Antibodies: Antagonism of Glucagon Action and Use in Receptor Characterization. Hormone and Metabolic Research. 28(5). 215–219. 7 indexed citations
10.
Timmann, Dagmar, Y.P. Shimansky, Paul Larson, et al.. (1996). Visuomotor learning in cerebellar patients. Behavioural Brain Research. 81(1-2). 99–113. 22 indexed citations
11.
König, Gerhard, et al.. (1996). Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl‐Terminus of the βA4 Peptide. Annals of the New York Academy of Sciences. 777(1). 344–355. 1 indexed citations
12.
Dreyer, Robert N., D. Wunderlich, D O Wirak, et al.. (1994). Processing of the Pre‐β‐amyloid Protein by Cathepsin d is Enhanced by a Familial Alzheimer's Disease Mutation. European Journal of Biochemistry. 224(2). 265–271. 58 indexed citations
13.
Wunderlich, D., et al.. (1992). Use of recombinant fusion proteins for generation and rapid characterization of monoclonal antibodies. Journal of Immunological Methods. 147(1). 1–11. 9 indexed citations
14.
Blue, M L, et al.. (1991). Human T cell activation by OKT3 is inhibited by a monoclonal antibody to CD44. The Journal of Immunology. 147(8). 2493–2499. 58 indexed citations
15.
Greve, J M, Carla Forte, Christopher W. Marlor, et al.. (1991). Mechanisms of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1. Journal of Virology. 65(11). 6015–6023. 118 indexed citations
16.
Kuroki, Manabu, Philip Fernsten, D. Wunderlich, et al.. (1990). Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies.. PubMed. 50(16). 4872–9. 38 indexed citations
17.
18.
Schlom, Jeffrey, David Colcher, Patricia Horan Hand, et al.. (1985). Monoclonal Antibodies Reactive With Breast Tumor-Associated Antigens. Advances in cancer research. 43. 143–173. 22 indexed citations
19.
Colcher, David, Patricia Horan Hand, Y A Teramoto, D. Wunderlich, & Jeffrey Schlom. (1981). Use of monoclonal antibodies to define the diversity of mammary tumor viral gene products in virions and mammary tumors of the genus Mus.. PubMed. 41(4). 1451–9. 26 indexed citations
20.
Gillette, Ronald W. & D. Wunderlich. (1978). Accelerated growth of mammary tumor cells in normal and athymic mice after treatment in vitro with dexamethasone.. PubMed. 38(10). 3146–9. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S M Hsu Breakdown of academic impact, for papers by John R. Adair Breakdown of academic impact, for papers by Sylvia Hu Breakdown of academic impact, for papers by Hajime Inomata Breakdown of academic impact, for papers by Susan F. Radka Breakdown of academic impact, for papers by Nathalie Renard Breakdown of academic impact, for papers by Elaine M. Elder Breakdown of academic impact, for papers by Gemma M. Dingjan Breakdown of academic impact, for papers by Bruce R. Ksander Breakdown of academic impact, for papers by Dimitrios Arvanitis
Rankless by CCL
2026